Links are provided to information about the DELIVER study, which is evaluating the safety and acceptability of the use of a monthly dapivirine ring or a daily antiretroviral pill (FTC/TDF, or Truvada) during pregnancy.

Aimed at potential study participants, this video provides background and describes the purpose and design of the Reversing the Epidemic in Africa with Choices in HIV prevention (REACH) study, or MTN-034. REACH is an open-label trial to evaluate how adolescent girls and young women use the monthly dapivirine vaginal ring and oral Truvada® (FTC/TDF) as daily pre-exposure prophylaxis (PrEP).

Published in the journal Culture and Behavior, this paper provides a synthesis of the adherence support experiences from four pivotal PrEP trials — the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004, FEM-PrEP, Iniciativa Prophylaxis (iPrEx), and Vaginal and Oral Interventions to Control the Epidemic (VOICE).

The HIV Prevention Trials Network (HPTN) is conducting a Phase 2b/3 double-blind safety and efficacy study of injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis among HIV-uninfected cisgender men and transgender women who have sex with men.